PULMONARY HYPERTENSION

1. PULMONARY HYPERTENSION ADIL K. WARSY M.D. PGYV PULMONARY FELLOW

2. FINANCIAL DISCLOSURES • None

3. OBJECTIVES • Learn to define the disorder • Classification and prevalence • Pathophysiology and histopathology • Presentation • Screening and diagnostic methods • Functional classification • Treatment approaches • Prognosis • PAH and pregnancy

4. DEFINITIONS • PULMONARY ARTERIAL HYPERTENSION Syndrome resulting from restricted blood flow through the pulmonary arterial circulation from vascular proliferation, aberrant remodeling and in situthrombosis resulting in increased pulmonary vascular resistance and ultimately right sided heart failure. • Hemodynamic state characterized by - Sustained elevation of mean pulmonary artery pressure to >25mm Hg at rest or >30mm Hg with exercise -Mean PCWP and LVEDP<15mm Hg

5. PULMONARY AND SYSTEMIC CIRCULATION • Standard pressures -Mean pulmonary artery pressure, 14mm Hg -PCWP, 8-12 mm Hg -LVEDP, 6-12 mm Hg -Systemic arterial pressure <120/80 mm Hg • PAH pressures -Mean pulmonary artery pressure > 25mm Hg -PCWP and LVEDP < 15 mm Hg -Systemic arterial pressure < 120/80 mm Hg

6. INCIDENCE/PREVALENCE • PAH is rare • Estimated prevalence of 3050 cases per million • Most common in young women • Mean age of diagnosis 36 years • The prevalence in certain at-risk groups is higher • HIV-infected patients (0.50%) • Sickle cell disease (2040%) • Systemic sclerosis (16%)5 • True prevalence may be higher

7. CLASSIFICATION • OLD CLASSIFICATION Primary and Secondary • In 1998 it was proposed to classify based on -Disorders in between the ones affecting the arterial part of pulmonary circulation -Disorders affecting venous part of the circulation -Disorders affecting the circulation by altered respiratory function.

8. CLASSIFICATION • Third World Conference on Pulmonary Hypertension, held in Venice, Italy, in 2003. The major changes noted in these revisions were as follows: (1)Replacement of the term primary PH with -Idiopathic pulmonary arterial hypertension (IPAH) -Familial pulmonary arterial hypertension (FPAH) when supported by genetic testing, (2) Abandonment of the term secondary PH

9. WHO CLASSIFICATION • Group I.Pulmonary arterial hypertension (PAH) • Idiopathic (IPAH) • Familial (FPAH) • Associated with (APAH): • Connective tissue disease • Congenital systemic-to-pulmonary shunts-Eisenmenger’s syndrome • Portal hypertension • HIV infection • Drugs and toxins • Other (thyroid disorders, glycogen storage disease, Gaucher's disease, hereditary haemorrhagic telangiectasia, haemoglobinopathies, myeloproliferative disorders, splenectomy • Associated with significant venous or capillary involvement • Pulmonary veno-occlusive disease (PVOD) • Pulmonary capillary haemangiomatosis (PCH) • Persistent pulmonary hypertension of the newborn (PPHN)

10. WHO CLASSIFICATION • Group II. Pulmonary hypertension associated with left heart diseases • Group III. Pulmonary hypertension associated with respiratory diseases and / or hypoxemia (including COPD) • Group IV. Pulmonary hypertension due to chronic thrombotic and/or embolic disease -Thromboembolic obstruction of proximal pulmonary arteries -Thromboembolic obstruction of distal pulmonary arteries -Pulmonary embolism (tumor, parasites, foreign material) -Sickle cell disease • Group V. Miscellaneous group eg. sarcoidosis, histiocytosis X and lymphangiomatosis

11. WHO GROUP I • IPAH (idiopathic pulmonary arterial hypertension - Leading cause almost 40% of the cases - No risk factor, family history or genetic mutation. - More common in women - Mean age 52

12. WHO GROUP I • FPAH (Familial pulmonary arterial hypertension) - At least 100 families have been identified world wide - Accounts for >6% of all cases of PAH - Pedigree analysis shows an autosomal dominant inheritance with reduced penetrance ( 10% to 20% of carriers are affected) - Two genes in TGF-B receptor family have been linked to FPAH - BMPR-2 and ALK-1 - Mutations in bone morphogenetic protein receptor type 2 (BMPR2) have been detected in approx. 71% of patients with FPAH - Mutations in BMPR2 have been detected in 26% of IPAH cases

14. PATHOPHYSIOLOGY • Exact cause of PAH remains unknown • Endothelial dysfunction occurs early on in the disease process • Endothelial dysfunction results in • Reduced production of vasodilators • Over production of vasoconstrictors • Endothelial and smooth muscle cell proliferation • Remodelling of the pulmonary vascular bed and increased pulmonary vascular resistance (PVR) • Increase in pulmonary vascular resistance (PVR) • Leads to right ventricular overload • Leads to right ventricular failure and premature death

15. PATHOPHYSIOLOGY • Three pathways are involved: 1. Prostacyclin (prostaglandin) 2. Nitric oxide (NO)− Cyclic guanosine monophosphate ( GMP)- phosphodiesterase 5 3. Endothelin • Platelets likely play an important role as pro-coagulants by increasing the platelet release of serotonin, vascular endothelial growth factor, and platelet-derived growth factor.

16. PATHOPHYSIOLOGY • Reduced production of vasodilators • Prostacyclin • potent vasodilator • potent inhibitor of platelet activation • therapy with synthetic forms of prostacyclin may help to correct this deficiency • Nitric oxide • potent vasodilator • possesses anti-proliferative properties • vasodilatory effect is mediated by cGMP • rapidly degraded by phosphodiesterases

17. PATHOPHYSIOLOGY • Increased production of vasoactive compounds • Endothelin (ET) • elevated levels are seen in PAH patients • levels correlate with disease severity • deleterious effects mediated through ETA and ETB receptors5 • fibrosis • hypertrophy and cell proliferation • inflammation • vasoconstriction • Endothelin receptor antagonists can block these effects • ET, nitric oxide and Prostacyclin have been the principal focus of research into treatments for PAH

18. DISEASE PATHWAY IN PAH

19. HISTOPATHOLOGY

20. PRESENTATION SYMPTOMS • High resistance to blood flow through the lungs causes right heart dysfunction and produces: • Dyspnea • Fatigue • Dizziness • Syncope • Peripheral edema • Anginal chest pain, particularly during physical exercise • Hemoptysis • Hoarseness • Anorexia • RUQ discomfort • Symptoms are non-specific and are commonly attributed to other conditions • Over time, symptoms become more severe and limit normal daily activities

21. PRESENTATION CLINICAL SIGNS • Jugular venous distension • Prominent P2 • Right ventricle heave • Tricuspid insufficiency murmur • Right side S3 heart sound • Hepatomegaly • Peripheral edema

22. WHY IT IS A DIAGNOSTIC DILEMMA? • Low awareness/not a condition seen every day by general physicians • It often comes in disguise: • Non-specific symptoms that are often mild and common to other conditions • Confusion with other diseases such as asthma, COPD and other cardiovascular disorders • No simple means of excluding PAH

23. STEPWISE APPROACH TO DIAGNOSE Diagnosis requires a series of investigations in a four-stage approach: • Clinical suspicion of pulmonary hypertension Symptoms, screening and incidental findings • Detection of pulmonary hypertension ECG, chest radiograph, Doppler echocardiography • Identification of other causes of pulmonary HTN Pulmonary function test, blood gas samples, HRCT • PAH evaluation and classification Functional capacity and hemodynamics

24. SCREENING HIGH RISK POPULATION • Key to early diagnosis – screening high risk populations: • Family members of a patient with familial Pulmonary Arterial Hypertension (FPAH) • Patients with systemic sclerosis (SSc) • Patients with HIV • Patients with portopulmonary hypertension (PoPH) • International guidelines recommend annual screening with Doppler echocardiography.1-3 • Right heart catheterisation still only method for definitive diagnosis

25. TOOLS FOR SCREENING • Clinical suspicion • History and Physical • Doppler echocardiography.

26. SCREENING HIGH RISK POPULATION • Results of a disease registry in France: • Without screening, the majority of patients were diagnosed in WHO FC III or FC IV, and only 24% of patients were in WHO FC II at diagnosis.

28. ECG

29. ECHOCARDIOGRAPHY Specificity moderate : PAP overestimated in patients with advanced lung disease

30. NONINVASIVE TESTING • Full PFTs with DLCO help identify COPD Interstitial lung disease • ABG • CT scan Lung pathology Pulmonary embolism • HRCT Interstitial lung disease

31. CT SCAN

32. CT SCAN

33. VQ SCAN in CTEPH

34. CLARIFY ETIOLOGY • Patients with PAH on echocardiogram • H/O EDS, snoring, apneas Obtain NPSG • Arthralgias, arthritis, myalgias, skin lesions Obtain serology for CTD • Risk of/ exposure to HIV • Screen for CTEPH Many patients will not have h/o VTE VQ scan should be ordered.

35. RIGHT HEART CATHETERISATION-THE GOLD STANDARD

36. RIGHT HEART CATHETERISATION-THE GOLD STANDARD • RHC should always assess • right atrial pressure (RAP) • systolic, diastolic and mean pulmonary arterial pressure (PAP) • pulmonary capillary wedge pressure (PCWP) • cardiac output / index • PVR and systemic vascular resistance • blood pressure and arterial and mixed venous oxygen saturation • RHC can assess vaso-reactive response • shown in only 1015% of patients • sustained response is shown in less than 7% of patients

37. RIGHT HEART CATHETERISATION-THE GOLD STANDARD

38. VASOREACTIVITY • Testing is done with right heart catheterization • Defined as mean pulmonary artery pressure decrease by at least 10 mm Hg to a level below 40 mm Hg, with no decrease in cardiac output. • Agents approved - Epoprostenol IV - Adenosine IV - Nitric oxide inhaled

39. FUNCTIONAL ASSESSMENT • WHO functional classification • 6 minute walk test (6 MWT) - Reliable, validated - Correlates with survival - Common endpoint in therapeutic trials

40. WHO FUNCTIONAL CLASSIFICATION • There are four WHO functional classes (WHO FC) • WHO FC I being the least severe • WHO FC IV being the most advanced Different classes reflect the impact on a patient’s life in terms of physical activity and symptoms

41. WHO FUNCTIONAL CLASSIFICATION • Class I Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause dyspnea or fatigue, chest pain or near syncope • Class II Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope • Class III Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope • Class IV Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest

42. 6 MINUTE WALK TEST • The 6-minute walk test (6MWT) is an evaluation of exercise capacity in patients with PAH and is used to determine the functional class and is also a prognostic indicator • The 6-MWT is a critical endpoint in clinical studies assessing therapeutic options • The 6-MWT should be performed under supervision and according to a standardised protocol

43. BIOMARKERS • N- TERMINAL Pro BNP • Hyponatremia - Neuro hormonally released Vasopressin induced - Strongly associated with RHF and poor prognosis

44. TREATMENT • There is currently no cure for PAH • Prognosis is influenced by the status of WHO FC when treatment is started – those who start therapy in WHO FC I or II demonstrate a better prognosis than those whose therapy is started in the more severe stages1 • By recognizing and treating patients as early as possible, disease progression may be delayed • Without treatment, patients in WHO FC II can rapidly deteriorate within 6 months to more advanced PAH as evidenced by progression of symptoms.

45. TREATMENT STRATEGY • Prevention • Screening of high risk patients • Optimize therapy for related disease • Supportive treatment ( aimed at consequences of PAH) • Vascular targeted therapy (aimed at reducing/ reversing vasoconstriction, proliferation) • Surgical ( atrial septostomy, lung transplantation)

46. SUPPORTIVE Anticoagulants - warfarin for prevention against in situ thrombosis INR goal is 2-2.5 Diuretics – for treatment of right heart failure Oxygen therapy – to maintain oxygen saturation at >90% at all times Pneumococcal and yearly influenza vaccination Digoxin Avoidance of High altitudes Air travel Pregnancy NSAID Tobacco use Heavy exertion Beta blockers Decongestant medications High Sodium diet Appetite suppressants

47. VASCULAR TARGETED THERAPIES • Prostacyclin pathway Beraprost (PO) Ilioprost (Inhaled) Epoprostenol (IV) Treprostinil (SQ,IV, inhaled) • NO pathway Dipyridamole(PO) Nitric oxide (inhaled) Sildenafal (PO) Taladafil (PO) • Endothelin pathway Ambrisentan (PO) ER-A antagonist Bosentan(PO) non selective

48. CALCIUM CHANNEL BLOCKERS • Never given empirically • Reserved for “responders” -Near normalization (PAP to 40 mm) and normal CO -High dose nifedipine or diltiazem -Only half of responders will have long term benefit -Response monitored and with deterioration treatment escalated

49.  Survival in patients with IPAH based on acute vasoreactivity and treatment with warfarin. In patients who were not vasoreactive, warfarin was associated with a modest survival advantage versus nonreactive patients who were not on warfarin.  (Redrawn from Rich S, Kaufmann RN, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81, 1992.)

50. COMBINATION THERAPY • Maximize therapy while minimize toxicity • 8 trials with 1600 patients published various combinations 6MWT as the primary endpoint 12 -16 weeks showed only modest improvement • Recommended for Class III and IV who fail to improve or class II with deterioration